Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.
(WorldNews Business)

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Sep 28, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or “the Company”) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®. This product expands Taro`s capabilities to include specialty products. Thalassemia syndromes are relatively rare in the United States, but are one of the most common autosomal recessive disorders in the world. The incidence of symptomatic cases is estimated to be approximately 1 in 100,000...